Prognosis
Pfizer Covid Vaccine for Younger Kids Wins FDA Panel’s Backing
- Signoff sets stage for expected authorization in coming days
- Shots for kids, boosters could recharge U.S. immunization push
This article is for subscribers only.
The benefits of a Covid-19 vaccine for young children made by Pfizer Inc. and BioNTech SE exceed its risks, according to a panel of U.S. experts, putting a shot for the youngest school-age children on track for a likely clearance.
The Food and Drug Administration’s vaccines advisory committee voted 17-0, with one abstention, to back the immunization, which is intended for children from 5 to 11 years old and is one-third the dose currently given to people age 12 and older.